Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo ...

From the election of Zohran Mamdani to the intrigue surrounding the jewel heist at the Louvre, keeping up with this year's news also left some Americans struggling with pronunciations. That's put both ...

Clinically diagnosed pruritus significantly affected fatigue and antidepressant use in adults with primary sclerosing cholangitis (PSC), based on data from nearly 5000 patients presented at The Liver ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary cholangitis (PBC). The pharma—which earned the FDA’s accelerated approval for PBC ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...

Cholangitis and cholecystitis are two conditions that share some similarities but have different causes and symptoms. Cholangitis affects the bile ducts, while cholecystitis affects the gallbladder.

AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis (PSC), ...

Your doctor may recommend a combination of medications, dietary supplements, and lifestyle changes to help manage primary biliary cholangitis (PBC). Some people eventually need a liver transplant to ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

Objective Most prognostic models for primary sclerosing cholangitis (PSC) are based on patients referred to tertiary care and may not be applicable for the majority of patients with PSC. The aim of ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid. People ...